PHILADELPHIA – About one-third of all genes in the mammalian genome are essential for life. An international, multi-institutional research collaboration identified, for the first time, mutant traits in the mouse for 52 human disease genes, which significantly contributes to the understanding of the genetic bases for some human diseases, including cardiovascular defects, spina bifida, and metabolic disorders, among many others. The study was published this week in Nature.
The group’s work is part of the International Mouse Phenotyping Consortium (IMPC), which is generating and assessing the physiological characteristics (phenotyping) of mutations for all of the protein-coding genes in the mouse genome. The Consortium aims to discover new functions for the roughly 20,000 genes mice share with humans and makes all of these mouse strains available to provide a platform for better understanding the mechanisms of human disease. The research team includes investigators from the Perelman School of Medicine at the University of Pennsylvania, The Jackson Laboratory, the Baylor College of Medicine, the University of Toronto, and the MRC Harwell Institute, United Kingdom.
The Nature study reports the results of the first 1,700-plus genes characterized by the IMPC, which includes 410 genes, that when mutated on both the maternal and paternal copy, are lethal to the mice and an additional 198 for which fewer than half of the expected number of mutants was identified.
This study is set apart by its use of high-throughput imaging with automated analysis to identify novel features that would have easily been missed using older technology. Employing a new, standardized phenotyping pipeline and mouse strains of a single specific genetic background called C57BL/6N, the researchers established both the time of embryo death and the nature of the lethal phenotypes for these lines, discovering many novel phenotypes that shed light on the function of these genes. Incorporation of the high-resolution, three-dimensional imaging and automated, computational analysis of the images allowed the team to rapidly gather detailed data, enabling the discovery of new phenotypes at an unprecedented scale.
The Penn team contributed to the bioinformatics analysis of essential genes in humans and showed their relevance to human disease. “The sheer amount of new data reported in this paper is impressive,” said co-author Maja Bucan, PhD, a professor of Genetics. “For years, a phenotype for just one knockout mouse would form the basis of a single paper, and this paper includes analysis of 410 knockouts. We compared the genes analyzed in this paper with a list of known human disease genes, which made it possible to identify for the first time the mutant phenotypes in the mouse for 52 human disease genes.” Mouse knockouts are genetically modified animals in which an existing gene has been inactivated for the purposes of studying the functions of sequenced genes.
“When looking across the seven or eight embryos generated for each of the 410 knockouts, we found variations in phenotype at a surprising frequency,” said co-author Steve Murray, PhD, senior research scientist at the Jackson Lab. “We expect diversity when we look across different genetic backgrounds, but this is the first large-scale documentation of mice with the same mutation, and otherwise same genetic makeup, that have different individual phenotypes.”
In addition, in collaboration with the Exome Aggregation Consortium, another large, international DNA-sequencing initiative, the IMPC showed that human versions of mouse essential genes are significantly depleted for harmful mutations in humans. “As a result, we surmise that these essential genes are strong candidates for undiagnosed and rare diseases,” said co-first author Xiao Ji, a doctoral student in the Bucan lab.
The IMPC calculated that only a small percentage of genes are studied by the broad research community. From this, the systematic approach to phenotyping and unrestricted access to data and mouse models provided by the IMPC promises to fill this large gap in understanding mammalian gene function. All data and images generated by the project are available to researchers, disseminated via an open-source web portal. The mouse models generated are also available to other researchers who may be investigating particular pathways or disease phenotypes.
The research collaboration also included co-first authors Mary E. Dickinson, PhD, the Kyle and Josephine Morrow Endowed Chair of Molecular Physiology and Biophysics at Baylor; Ann Flenniken and Michael Wong, University of Toronto; and Lydia Teboul, PhD, head of molecular and cellular biology at Harwell. Mark Henkelman, PhD, director of the Mouse Imaging Centre, at Toronto, is also a co-author.
This work was supported by the National Institutes of Health’s National Human Genome Research Institute and the Office of the Director’s Common Fund (U42 OD011185, U54 HG006332, U54 HG006348-S1, OD011174, HG006364-03S1, U42 OD011175, U54 HG006370). Additional support was provided by The Wellcome Trust, Medical Research Council Strategic Award, Government of Canada through Genome Canada and Ontario Genomics (OGI-051), Wellcome Trust Strategic Award “Deciphering the Mechanisms of Developmental Disorders (WT100160), National Centre for Scientific Research, the French National Institute of Health and Medical Research, the University of Strasbourg, the “Centre Européen de Recherche en Biologie et en Médecine”, the Agence Nationale de la Recherche under the frame programme Investissements d’Avenir (ANR-10-IDEX-0002-02, ANR-10-INBS-07 PHENOMIN), The German Federal Ministry of Education, and Research by Infrafrontier (01KX1012).
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.